Sickle Cell Disease (SCD) is an inherited blood disorder in which red blood cells adopt a sickle-like shape. This can lead to blood vessel occlusion, chronic pain, fatigue, anemia, increased susceptibility to infections, organ damage, and a reduced life expectancy. The disease was first described in 1910. For many years, patients had access only to symptom relief, but today medicine has entered a new era.
In 2025, a Long Island resident, Sébastien Bozili, became the first patient in New York State to be fully cured of sickle cell disease with the help of gene therapy. He was treated at Cohen Children’s Medical Center.
How does gene therapy work?
The treatment used, called Lyfgenia, is a gene therapy that relies on the patient’s own stem cells. The process includes:
-
collecting stem cells from the bone marrow,
-
genetically modifying these cells in a laboratory setting,
-
reinfusing the modified cells back into the patient’s body.
As a result, the body begins producing healthy red blood cells, which reduces or completely prevents sickling. In Sébastien Bozili’s case, chronic pain resolved completely, blood circulation normalized, and quality of life improved dramatically.
The U.S. Food and Drug Administration (FDA) granted official approval for gene therapy for the treatment of sickle cell disease two years ago. This means the treatment is moving beyond the experimental stage into clinical practice and is becoming a real therapeutic option. However, it is important to note that gene therapy:
-
is a highly advanced and intensive procedure,
-
carries certain risks,
-
is extremely expensive, which remains one of the biggest barriers to broad access.
Gene therapy for sickle cell disease represents one of the most significant medical breakthroughs of recent decades. Despite high costs and the ongoing need for further research, this approach offers patients, for the first time, not only symptom management but the possibility of a true cure. In the future, as technology advances and access expands, gene therapy may become a standard treatment, including for communities that have historically been less represented in clinical innovation.
